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Abstract
To investigate the safety and practicability of conducting transtho-
racic ﬁne-needle aspiration (TFNA) in a general hospital setting,
we applied the TFNA procedure to 20 patients hospitalized with
community-acquired pneumonia (CAP) within 36 h of admission.
Also, a preliminary assessment was made of the potential value of
adding TFNA to conventional methods of diagnostic microbiol-
ogy. TFNA was easy to perform and caused little discomfort, and
no serious adverse events were observed. In spite of ongoing
antimicrobial treatment, a likely aetiological diagnosis was estab-
lished for 14 of 20 (70%) of the patients. TFNA may provide
important additional information on the aetiology of CAP.
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The main aims of this pilot study were to investigate the
safety and practicability of conducting transthoracic ﬁne-
needle aspiration (TFNA) to reach the aetiological diagnosis
of community-acquired pneumonia (CAP) in a general
hospital setting. Also, a preliminary assessment was made of
the diagnostic value of adding TFNA to conventional meth-
ods of clinical microbiology. We conducted TFNA under
ﬂuoroscopic guidance on 20 CAP patients (mean age
57 years, range 21–80 years). TFNA was performed under
sterile conditions, using local anaesthesia. A 22-gauge
needle, stylet removed, was attached to a 10-mL syringe
containing 5 mL of isotonic saline; under ﬂuoroscopic
guidance, the needle was introduced into the pulmonary
inﬁltrate. Four millilitres of the saline were injected into the
inﬂamed area, leaving approximately 1 mL as carrier ﬂuid in
the syringe. Negative pressure was applied while the needle
was slowly retracted. Chest X-ray images were taken
during both inspiration and expiration 1–2 h after the
TFNA procedure.
Pending PCR examination, 500 lL of the aspirate was
divided into two aliquots and frozen at )70C. As was the
case with TFNA, samples for conventional microbiological
examination were collected within 36 h of hospital admission
(Table 1).
The pulmonary aspirates were examined using a real-time
PCR speciﬁc for a 587-bp region (between positions 341 and
927) of the 16S RNA gene of bacteria; the PCR products
were sequenced using a 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA), and the sequences were
analysed with Sequencing Analysis 5.2 (Applied Biosystems).
The consensus sequences were compared with sequences in
the GenBank database for identiﬁcation using NCBI BLAST.
Our diagnostic repertoire included real-time quantitative
PCR targeting the fumarate reductase (frdB) gene of Haemo-
philus inﬂuenzae and the outer membrane protein (copB) gene
of Moraxella catarrhalis, as described by Kais et al. [1], and
detection of Streptococcus pneumoniae using primers targeting
spn9802 [2]. Pneumococcal genomic DNA was ampliﬁed in a
QantiTect SYBR Green PCR assay (VWR International AB,
Stockholm, Sweden), performed with a Rotor-Gene 3000
instrument (Corbett Research, Mortlake, Sydney, Australia).
Dilutions of genomic DNA extracted from S. pneumoniae
CCUG 28588, M. catarrhalis CCUG 18284 and H. inﬂuenzae
CCUG 23969 (Culture Collection, University of Gothenburg,
Sweden) were used as positive controls. Melting curve analy-
ses were performed to ensure the speciﬁcity of the ampliﬁed
products.
The oropharyngeal swabs were examined using virus-
speciﬁc real-time PCR assays based on TaqMan technology,
all validated for routine diagnostic use.
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TABLE 1. Tests performed on con-
ventional samples and pulmonary
aspirate
Conventional
tests
Blood culture BacT/ALERT PF bottle (BioMe´rieux) for 5 days
Sputum culture
Oropharyngeal swabs Mycoplasma pneumoniaea,b, Chlamydophila pneumoniaea,b,
Bordetella pertussisa,b, Streptococcus pneumoniaeb, adenovirusb,
human bocavirusb, coronavirus (OC43, 229E and NL63)b,
enterovirusb, human metapneumovirusb, inﬂuenza A and B virusb,
parainﬂuenza virus types 1–4b, RS virusb, and rhinovirusb
Paired serum (sample
obtained at hospital
admission and after
4 weeks)
B. pertussisa (B. pertussis ﬁlamentous haemagglutinin IgA and
B. pertussis toxin IgG, Pertusscan Trok; Euro-Diagnostica AB,
Malmo¨, Sweden)
M. pneumoniaea (Novitec M. pneumoniae IgG and IgM
antibody test; Hiss Diagnostics, Freiburg, Germany)
C. pneumoniaea (C. pneumoniae IgG and IgM test;
Ani Labsystems Ltd, Vantaa, Finland)
Adenovirusa (Serion KBR Adenovirus, Wu¨rzburg, Germany)
Inﬂuenza A and B virusa (Serion KBR Inﬂuenza A virus
and Serion KBR Inﬂuenza B virus)
Urinary antigen test
(non-concentrated urine)
Binax Now Urinary antigen test for S. pneumoniae and
Legionella pneumophila (Binax Inc., Scarborough, ME, USA)
Lung
aspirate
Culture BacT/ALERT PF bottle (BioMe´rieux) for 5 days
Gram-stained smear Microscopy for leukocytes and microbesa
PCR M. pneumoniaea,b, C. pneumoniaea,b, B. pertussisa,b, adenovirusb,
human bocavirusb, coronavirus (OC43, 229E and NL63)b,
enterovirusb, human metapneumovirusb, inﬂuenza A and B virusb,
parainﬂuenza virus types 1–4b, RS virusb, rhinovirusb,
S. pneumoniaeb,c, Moraxella catarrhalisc, Haemophilus inﬂuenzaec
Rapid tests Slidex Me´ningite kit (BioMe´rieux, Marcy l’Etoile, Francea)
aDepartment of Microbiology, Sorlandet Hospital Kristiansand, Norway.
bDepartment of Medical Microbiology, St Olav’s Hospital, Trondheim, Norway.
cDepartment of Clinical Microbiology at Karolinska University Hospital, Stockholm, Sweden.
TABLE 2. Deﬁnite and presumptive community-acquired pneumonia pathogens
Patient Blood culture Sputum culture Urinary antigen Paired sera
Oropharynx
PCR
TFNA
Culture PCR
1 – Staphylococcus aureus,
Haemophilus inﬂuenzae
– Mycoplasma pneumoniae – S. aureus S. aureus
2 Streptococcus
pneumoniae
Not representative
material
Streptococcus
pneumoniae
– – – Streptococcus
pneumoniae
3 – No sample obtained – M. pneumoniae – – –
4 – – – – – – Streptococcus
pneumoniae
5 – No sample obtained – – – – Streptococcus
pneumoniae
6 – – – M. pneumoniae M. pneumoniae – M. pneumoniae,
PI4
7 – – – – – – –
8 – – – – – – –
9 – Moraxella catarrhalis – – – – –
10 – – – – – – –
11 – Not representative
material
Streptococcus
pneumoniae
– CorOC43 – –
12 – – – – Rhinovirus – –
13 – Not representative
material
– – – – Streptococcus
pneumoniae,
H. inﬂuenzae
14 – Not representative
material
– – – – –
15 – – – Inﬂuenza A virusa – – H. inﬂuenzae
16 – No sample obtained Streptococcus
pneumoniae
– – – Streptococcus
pneumoniae
17 – – – M. pneumoniae M. pneumoniae – M. pneumoniae,
H. inﬂuenzae
18 – – Streptococcus
pneumoniae
– – – Streptococcus
pneumoniae,
H. inﬂuenzae
19 – No sample obtained – – – – –
20 – No sample obtained – – – – H. inﬂuenzae
– , Negative test; PI4, parainﬂuenza virus 4; CorOC43, coronavirus OC43; TFNA, transthoracic ﬁne-needle aspiration.
aThe patient received inﬂuenza A vaccination a few days prior to hospital admission.
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The TFNA procedure was easy to perform, and there
were no serious adverse events. Two patients developed a
minor, self-limiting pneumothorax, and seven patients
reported pin-point-sized haemoptysis. A deﬁnite aetiology of
CAP was established in 12 of 20 (60%) of the cases, in eight
cases (40%) by TFNA alone (Table 2). When presumptive
aetiologies were included, a diagnosis was established for 14
of 20 (70%) of the patients. Except for one patient who was
positive both by culture and 16S rRNA gene-targeting PCR,
all PCR-positive aspirates were identiﬁed as such using real-
time PCR methods.
Our study shows that TFNA is technically feasible in a
busy general hospital setting, and conﬁrms that the proce-
dure is associated with mild discomfort only, although careful
follow-up disclosed a minimal and clinically insigniﬁcant pneu-
mothorax in two of 20 (10%) of the cases. Davidson et al.
[3] reported that their patients preferred TFNA to tran-
stracheal aspiration, and in one study TFNA was considered
to be about as painful as venipuncture [4]. Large reviews
representing a total of more than 3000 TFNA procedures
found the overall risk of pneumothorax to be 3.3%. Chest
drainage was required in 0.5% of these cases [5,6].
Whereas aetiological diagnosis based on bacterial culture
is likely to suffer from hours of antibacterial treatment
before TFNA, PCR-based diagnostics may be relatively unaf-
fected. In a study by Ruiz-Gonzalez et al. [7], an aetiological
diagnosis of CAP was obtained for 50% of the study group,
using conventional methods. This success rate increased to
83% with the use of TFNA.
In patients treated with antibiotics before admission,
S. pneumoniae was detected by culture of TFNA material in
33% of the patients, whereas PCR revealed the aetiology in
the same material in 83.3% of the cases [8]. In our small
study, an aetiology was found in 14 of 20 (70%) of the cases,
in eight cases (40%) solely by TFNA. This is the ﬁrst study of
the aetiology of CAP in which the diagnostic procedure was
routinely performed as late as 36 h after admission. The fact
that all patients had received antibiotic treatment before
undergoing TFNA may explain why the aetiology was rarely
conﬁrmed by culture.
We conclude that, in our hospital setting, TFNA is a safe
and practicable method for the aetiological diagnosis of CAP.
Studies are ongoing to assess whether extensive use of
TFNA will substantially improve the aetiological diagnosis of
CAP and, if so, result in speciﬁcally targeted antimicrobial
treatment in our hospital.
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